Plain-English translation of NCT06168032 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a COVID-19 booster vaccine can help protect people with lung cancer from catching COVID-19 again. You would receive one booster dose (depending on which vaccine your country approves) and have your blood tested at several timepoints to measure your immune response. The study will track whether vaccinated participants have fewer COVID-19 reinfections, serious illness, or other health problems compared to those who choose not to get vaccinated.
People with lung cancer who are on chemotherapy or immunotherapy have weakened immune systems and may be at higher risk for severe COVID-19 and reinfection. This study wants to understand whether this medication works well in this vulnerable group and how their bodies respond to it differently than healthy people.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive a booster vaccine dose (6 months after your last COVID-19 infection) or choose not to be vaccinated. Either way, you will have blood drawn three times — at 3 months, 4.5 months, and 6 months after your most recent COVID-19 infection, and again at the same timepoints after your booster dose (if you receive it). For the next 6 months after vaccination or your enrollment date, researchers will monitor you for any new COVID-19 infections, serious illness, or other health changes.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China